ATE347550T1 - Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure - Google Patents

Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure

Info

Publication number
ATE347550T1
ATE347550T1 AT02724323T AT02724323T ATE347550T1 AT E347550 T1 ATE347550 T1 AT E347550T1 AT 02724323 T AT02724323 T AT 02724323T AT 02724323 T AT02724323 T AT 02724323T AT E347550 T1 ATE347550 T1 AT E347550T1
Authority
AT
Austria
Prior art keywords
alpha
polymorphous
ethoxyethyl
benzimidazole
piperidinyl
Prior art date
Application number
AT02724323T
Other languages
English (en)
Inventor
Venero Aurelio Orjales
Martin Maravillas Bordell
Mori Gonzalo Canal
Fuente Haydee Blanco
De Pablo Maria Luisa Lucero
Royo Victor Rubio
Pestana Ramon Mosquera
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE347550(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Application granted granted Critical
Publication of ATE347550T1 publication Critical patent/ATE347550T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02724323T 2002-04-19 2002-04-19 Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure ATE347550T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2002/000194 WO2003089425A1 (es) 2002-04-19 2002-04-19 POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO

Publications (1)

Publication Number Publication Date
ATE347550T1 true ATE347550T1 (de) 2006-12-15

Family

ID=29225789

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02724323T ATE347550T1 (de) 2002-04-19 2002-04-19 Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure

Country Status (30)

Country Link
US (2) US7612095B2 (de)
EP (1) EP1505066B1 (de)
JP (1) JP5142448B2 (de)
KR (1) KR100673140B1 (de)
CN (1) CN1290843C (de)
AR (1) AR039423A1 (de)
AT (1) ATE347550T1 (de)
AU (1) AU2002255017B2 (de)
BG (1) BG66302B1 (de)
BR (1) BRPI0215703B8 (de)
CA (1) CA2484460C (de)
CY (2) CY1107564T1 (de)
CZ (1) CZ305162B6 (de)
DE (1) DE60216641T2 (de)
DK (1) DK1505066T3 (de)
ES (1) ES2278018T3 (de)
HR (1) HRP20041048B1 (de)
HU (1) HU230032B1 (de)
IL (1) IL164645A (de)
MX (1) MXPA04010313A (de)
NO (1) NO329327B1 (de)
NZ (1) NZ536551A (de)
PA (1) PA8571201A1 (de)
PE (1) PE20040086A1 (de)
PT (1) PT1505066E (de)
SI (1) SI1505066T1 (de)
SK (1) SK288052B6 (de)
UA (1) UA76866C2 (de)
UY (1) UY27762A1 (de)
WO (1) WO2003089425A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
JP6023054B2 (ja) * 2011-06-30 2016-11-09 パナソニック インテレクチュアル プロパティ コーポレーション オブ アメリカＰａｎａｓｏｎｉｃ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｃｏｒｐｏｒａｔｉｏｎ ｏｆ Ａｍｅｒｉｃａ 通信システム、ユーザ端末並びに通信装置
CN102675101B (zh) * 2012-05-16 2014-01-29 王蕾 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法
CZ307500B6 (cs) 2012-08-15 2018-10-24 Zentiva, K.S. Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty
CN103214454A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 一种比拉斯汀晶型及制备方法
WO2014188453A2 (en) * 2013-05-24 2014-11-27 Msn Laboratories Private Limited Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
CN103356616A (zh) * 2013-06-29 2013-10-23 北京万全德众医药生物技术有限公司 一种含有比拉斯汀的药物组合物及其制备方法
CN104447682A (zh) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 比拉斯汀化合物
CN104398481A (zh) * 2014-10-29 2015-03-11 万全万特制药江苏有限公司 比拉斯汀口崩片及其制备方法
KR102657147B1 (ko) * 2015-07-24 2024-04-12 울퀴마, 에스. 에이. 빌라스틴의 결정형 및 그의 제조 방법
EP3170816A1 (de) * 2015-11-20 2017-05-24 Faes Farma, S.A. Übersättigte zusammensetzungen von benzimidazolverbindungen
EP3170817A1 (de) * 2015-11-20 2017-05-24 Faes Farma, S.A. Cokristalle von benzimidazolverbindungen
WO2017167949A1 (en) 2016-04-01 2017-10-05 Krka, D.D., Novo Mesto Crystalline forms of bilastine
WO2017191651A1 (en) * 2016-05-05 2017-11-09 Msn Laboratories Private Limited, R & D Center Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof
EP3453384B1 (de) 2017-09-07 2020-05-27 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmazeutische tablette enhaltend bilastin
EP3641735B1 (de) 2017-12-18 2021-02-24 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmazeutische tablettenzusammensetzung mit bilastinform 3 und wasserlöslichem füllstoff
ES2835287T3 (es) 2017-12-18 2021-06-22 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica de comprimido que comprende la forma polimórfica 3 de bilastina y aluminometasilicato de magnesio
CA3088740A1 (en) 2018-01-18 2019-07-25 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
WO2022135863A1 (en) 2020-12-23 2022-06-30 Biohorm, S.L. A non-micronized bilastine composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
TR200103851T2 (tr) * 1999-04-16 2002-04-22 Dr. Reddy' S Research Foundation Bir antidiyabetik maddenin yeni polimorfik formları, bunların hazırlanması için işlem ve bunları farmasötik bileşimler
PL351684A1 (en) * 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt

Also Published As

Publication number Publication date
CA2484460C (en) 2009-09-29
BG66302B1 (bg) 2013-03-29
CN1290843C (zh) 2006-12-20
EP1505066A1 (de) 2005-02-09
CY2013015I1 (el) 2015-08-05
CA2484460A1 (en) 2003-10-30
HRP20041048A2 (en) 2005-02-28
HRP20041048A9 (hr) 2013-01-31
HU230032B1 (hu) 2015-05-28
WO2003089425A1 (es) 2003-10-30
KR100673140B1 (ko) 2007-01-22
CY1107564T1 (el) 2013-03-13
CZ20041122A3 (cs) 2005-03-16
UY27762A1 (es) 2003-09-30
AR039423A1 (es) 2005-02-16
BG108941A (en) 2005-12-30
EP1505066B1 (de) 2006-12-06
CY2013015I2 (el) 2015-08-05
SK288052B6 (sk) 2013-03-01
CZ305162B6 (cs) 2015-05-27
MXPA04010313A (es) 2005-06-08
UA76866C2 (uk) 2006-09-15
ES2278018T3 (es) 2007-08-01
PE20040086A1 (es) 2004-04-27
NO329327B1 (no) 2010-09-27
AU2002255017B2 (en) 2008-11-13
NZ536551A (en) 2006-08-31
KR20050005448A (ko) 2005-01-13
BRPI0215703B1 (pt) 2017-06-27
US20050203141A1 (en) 2005-09-15
HUP0500241A2 (hu) 2005-06-28
IL164645A0 (en) 2005-12-18
US20100004285A1 (en) 2010-01-07
AU2002255017A1 (en) 2003-11-03
DE60216641D1 (de) 2007-01-18
HRP20041048B1 (hr) 2013-04-30
IL164645A (en) 2010-11-30
BR0215703A (pt) 2005-02-01
US7612095B2 (en) 2009-11-03
CN1628112A (zh) 2005-06-15
JP5142448B2 (ja) 2013-02-13
JP2005529120A (ja) 2005-09-29
SK50202004A3 (sk) 2005-05-05
SI1505066T1 (sl) 2007-04-30
PT1505066E (pt) 2007-03-30
HK1072772A1 (en) 2005-09-09
BRPI0215703B8 (pt) 2021-05-25
PA8571201A1 (es) 2003-12-10
DE60216641T2 (de) 2007-09-27
NO20044999L (no) 2005-01-14
DK1505066T3 (da) 2007-03-19

Similar Documents

Publication Publication Date Title
NO2017035I1 (no) Nintedanib, 3-Z-{1-(4-(N-((4-metyl-piperazin-1-y-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenylmetylenj- 6-metoksykarbonyl-2-indolinon
SI1505066T1 (sl) Polimorf 4-(2-(4-(1-(2-etoksietil)-1h-benzimidazol-2-il) -1-piperidinil)-alfa, alfa-dimetil-benzenocetne kisline
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
EE200400019A (et) 1-[4-(5-tsüanoindool-3-üül)butüül]-4-(2-karbamoüülbensofuraan-5-üül)piperasiinvesin ikkloriidi polümorfsed vormid
DE60303147D1 (de) Neues 2-pyridylethylbenzamid-derivat
DE60330227D1 (de) N3-alkylierte benzimidazol-derivate als mek-hemmer
NO20043997L (no) 4-(N-fenylamino)-kinazoliner/kinoliner som tyrokinaseinhibitorer
LTPA2016037I1 (lt) Nauji heterocikliniai junginiai, veiksmingi kaip beta-laktamazės slopikliai
SI1870100T1 (sl) Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline
DK2301544T3 (da) Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
DE60320933D1 (de) Rho-kinase inhibitoren
DK2281815T3 (da) 4-(Acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-1-acetic acid ethyl ester intermediate compound
ATE525377T1 (de) Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
DE60305061D1 (de) 2-pyridonderivate als inhibitoren von neutrophiler elastase
IL188207A (en) 1 - [2 - (3-Tret-Butyl Oreido) -3,3-Dimethylbutyril] -4- (7-Methoxy-2-Pyrazole-1-Il-Quinoline-4-Oxyl) -Pyrrolidine-Carboxylic Acid (1 -Cyclopropylamino oxalibutyl) affluent and uses
ATE455767T1 (de) Heterozyklische vegfr-2 kinase inhibitoren
NO20070368L (no) Virale polymeraseinhibitorer
DK1585743T3 (da) 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme
ATE419250T1 (de) 2-cyanopyrrolidincarbonsäureamide als dipeptidylpeptidase-iv-inhibitoren
ATE361296T1 (de) Pyrazolidin-1,2-dicarbonsäure-1-((phenyl)-amid) 2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
DK1838697T3 (da) Fremgangsmåder til at fremstille 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)-piperidin-1-carboxylsyre-derivater og relaterede forbindelser
DK1713801T3 (da) Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
DE60319836D1 (de) Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
ATE491692T1 (de) 1-(imidazolin-2-yl)amino-1,2-diphenylethan- verbindungen zur bekämpfung von tierpestkrankheiten
EP1711477A4 (de) Neue kristalline formen eines inhibitors von 11-beta-hydroxysteroiddehydrogenase typ 1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1505066

Country of ref document: EP